Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy

NCT06920251 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Relapsed Refractory Multiple Myeloma (RRMM)

Interventions

DRUG: Letermovir

Sponsor

Seoul National University Hospital